Evidence map›Paper›PMID 29453615›Full record

ArticlePflugers Archiv : European journal of physiology2018

Vidarabine, an anti-herpesvirus agent, prevents catecholamine-induced arrhythmias without adverse effect on heart function in mice.

Kenji Suita, Takayuki Fujita, Wenqian Cai, Yuko Hidaka, Huiling Jin, Rajesh Prajapati, Masanari Umemura, Utako Yokoyama, Motohiko Sato, Björn C Knollmann and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pflugers Archiv : European journal of physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Prospective Study on the Postoperative Use of Levosimendan After Conventional Heart Valve Replacement.Medical science monitor : international medical journal of experimental and clinical research · 2021
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Kenji SuitaCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Takayuki FujitaCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan. fujitaka@yokohama-cu.ac.jp.
Wenqian CaiCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yuko HidakaCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Huiling JinCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Rajesh PrajapatiCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Masanari UmemuraCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Utako YokoyamaCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Motohiko SatoCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Björn C KnollmannVanderbilt Center for Arrhythmia Research and Therapeutics, Vanderbilt University School of Medicine, Nashville, TN, USA.
Satoshi OkumuraCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yoshihiro IshikawaCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan. yishikaw@med.yokohama-cu.ac.jp.
Yokohama City University · JPCardiovascular Institute Hospital · JPTsurumi University · JPVanderbilt University · US

Funding

Japan Agency for Medical Research and Development 66890001Japan Agency for Medical Research and Development 66890005Japan Agency for Medical Research and Development 66890011Japan Agency for Medical Research and Development 66890023Japan Society for the Promotion of Science 15K18973Japan Society for the Promotion of Science 16K08501Japan Society for the Promotion of Science 23591087Japan Society for the Promotion of Science 24390200Japan Society for the Promotion of Science 24790219Japan Society for the Promotion of Science 25460296Japan Society for the Promotion of Science 25670131Ministry of Education, Culture, Sports, Science and Technology 22136009National Cerebral and Cardiovascular Center (NCVC) 22-2-3New Energy and Industrial Technology Development Organization 60890021
6 · The paper itself

Abstract

Sympathetic activation causes clinically important arrhythmias including atrial fibrillation (AF) and ventricular tachyarrhythmia. Although the usefulness of β-adrenergic receptor blockade therapy is widely accepted, its multiple critical side effects often prevent its initiation or continuation. The aim of this study is to determine the advantages of vidarabine, an adenylyl cyclase (AC)-targeted anti-sympathetic agent, as an alternative treatment for arrhythmia. We found that vidarabine, which we identified as a cardiac AC inhibitor, consistently shortens AF duration and reduces the incidence of sympathetic activation-induced ventricular arrhythmias. In atrial and ventricular myocytes, vidarabine inhibits adrenergic receptor stimulation-induced RyR2 phosphorylation, sarcoplasmic reticulum (SR) Ca

Indexed as

Adenylyl Cyclase InhibitorsAnimalsAnti-Arrhythmia AgentsAntiviral AgentsArrhythmias, CardiacCalcium SignalingCatecholaminesHeartHerpesviridaeMiceMice, Inbred C57BLMyocytes, CardiacVidarabineAdenylyl Cyclase InhibitorsAnti-Arrhythmia AgentsAntiviral AgentsCatecholaminesVidarabineAdenylyl cyclaseArrhythmiaBeta-adrenergic receptor blockerCatecholamineDrug therapy

Identifiers

PMID29453615
OpenAlexW2790613277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.